格菲妥单抗治疗复发/难治性B细胞淋巴瘤的疗效及影响因素分析
佳 丛, 承稷 王, 娜 姚, 磊 杨, 鑫 李, 进 叶, 晶 杨, 立强 魏, 亮 王 · 2026
Read 格菲妥单抗治疗复发/难治性B细胞淋巴瘤的疗效及影响因素分析 by 佳 丛, 承稷 王, 娜 姚, 磊 杨, 鑫 李, 进 叶, 晶 杨, 立强 魏, 亮 王 (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13416538.txt.
Description
Cong and co-authors review outcomes for a dual target antibody drug in returning B cell lymphoma in a 2026 study. Thirty-two patients at one Beijing hospital got regimens built on the drug. The team tracked survival, response, and safety over a median follow up beyond one year. Models hunted factors that shape time without disease growth.
About half of judged salvage patients responded, and all bridge therapy patients shrank their tumors in part. Release syndrome struck about a quarter of patients, all at mild grades. More past therapy lines and past cell therapy raised risk of early growth. Single drug use fared worst in hard treated cases. Paired regimens may serve better, with closer watch for side effects.
Catalog record
| CREATOR | 佳 丛, 承稷 王, 娜 姚, 磊 杨, 鑫 李, 进 叶, 晶 杨, 立强 魏, 亮 王 |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 17 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |